Corticotropin Releasing Hormone (CRH)
Introduction
Corticotropin Releasing Hormone (Crh) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@hauger2022]
<div class="infobox-header">Corticotropin Releasing Hormone (CRH)</div> [@joels2019]
<div class="infobox-row"><strong>Gene:</strong> [CRH](/proteins/crh-protein)</div> [@bale2020]
<div class="infobox-row"><strong>UniProt ID:</strong> [P06850](https://www.uniprot.org/uniprot/P06850)</div> [@de2018]
<div class="infobox-row"><strong>Molecular Weight:</strong> 4.6 kDa (precursor), 1.7 kDa (mature peptide)</div>
<div class="infobox-row"><strong>Amino Acid Length:</strong> 41 amino acids (mature peptide)</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Secretory vesicles, dense-core granules</div>
<div class="infobox-row"><strong>Protein Family:</strong> CRH/Urocortin family (tetra-neuropeptide family)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> AD, PD, HD, Depression, Anxiety, PTSD, Stroke, TBI</div>
</div>
Overview
Corticotropin Releasing Hormone (CRH), also known as Corticotropin-Releasing Factor (CRF), is a 41-amino acid neuropeptide that serves as the primary regulator of the hypothalamic-pituitary-adrenal (HPA) axis and a central coordinator of the stress response. First isolated and characterized in 1981 by Vale and colleagues, CRH is expressed in hypothalamic paraventricular nucleus (PVN) [neurons](/entities/neurons) that project to the median eminence, releasing CRH into the hypophyseal portal circulation to stimulate ACTH release from the anterior pituitary. Beyond its endocrine role, CRH acts as a neurotransmitter and neuromodulator throughout the brain, influencing emotional states, arousal, motivation, and complex behaviors. The CRH system includes two receptor subtypes (CRHR1 and CRHR2) and three related peptides (urocortin 1, 2, and 3), forming a sophisticated signaling network that is critically involved in both normal physiology and the pathophysiology of stress-related neurodegenerative and psychiatric disorders.
Normal Function
HPA Axis Regulation
CRH is the principal hypothalamic releasing factor controlling the stress response. Under basal conditions, CRH neurons in the PVN exhibit circadian rhythm activity, with peak secretion in the early morning hours. In response to stress—physical, psychological, or metabolic—CRH neurons are activated, releasing CRH into the median eminence. CRH then binds to CRHR1 receptors on anterior pituitary corticotrophs, stimulating proopiomelanocortin (POMC) cleavage and ACTH release. ACTH travels through systemic circulation to the adrenal [cortex](/brain-regions/cortex), stimulating cortisol synthesis and release. This cascade constitutes the final common pathway for stress hormone mobilization. Glucocorticoids, in turn, provide negative feedback on CRH neurons through glucocorticoid receptor-mediated inhibition.
Stress Response Coordination
Beyond the HPA axis, CRH neurons project throughout the brain to coordinate behavioral and autonomic responses to stress. CRH is released in the amygdala, bed nucleus of the stria terminalis (BNST), hippocampus, locus coeruleus, and prefrontal cortex. In these regions, CRH modulates anxiety-related behavior, fear conditioning, arousal, attention, and decision-making. CRH neurons in the parabrachial nucleus coordinate visceral responses to threat, while projections to autonomic nuclei regulate cardiovascular and respiratory responses. The CRH system thus provides a centralized mechanism for integrating psychological and physiological stress responses.
Cognitive and Emotional Processing
CRH influences cognition and emotion through modulation of synaptic plasticity and neurotransmitter systems. In the hippocampus, CRH at moderate concentrations enhances memory consolidation, particularly for emotionally salient information. However, chronic stress and excessive CRH exposure impair hippocampal function, reducing neurogenesis and causing dendritic atrophy. In the amygdala, CRH promotes anxiety-like behavior and fear conditioning. The balance between CRH activity in the hippocampus versus amygdala may determine whether stress is adaptive or maladaptive.
Sleep-Wake Regulation
CRH exhibits complex interactions with arousal systems. CRH levels are highest during waking, decline during slow-wave sleep, and are minimal during REM sleep. CRH administration increases wakefulness and reduces both SWS and REM sleep. Interactions between CRH and orexin/hypocretin systems may underlie stress-induced insomnia. Conversely, sleep deprivation activates CRH neurons, creating a bidirectional relationship between sleep disruption and stress sensitivity.
Role in Neurodegenerative Diseases
Alzheimer's Disease
CRH system alterations contribute to multiple aspects of AD pathophysiology. Chronic stress exposure, which elevates CRH levels, accelerates [amyloid-beta](/proteins/amyloid-beta) (Aβ) deposition in animal models. CRH can increase [BACE1](/entities/bace1) expression and activity, promoting amyloidogenic [APP](/entities/app-protein) processing. Additionally, CRH enhances [tau](/proteins/tau) phosphorylation through multiple kinases. The neurotoxic effects of glucocorticoid excess (downstream of CRH activation) are well-documented in the hippocampus. CRH may also modulate neuroinflammation; CRHR1 activation on [microglia](/entities/microglia) can promote pro-inflammatory cytokine release. Therapeutic strategies targeting CRH signaling may therefore have disease-modifying potential in AD.
Parkinson's Disease
Parkinson's disease involves bidirectional relationships between the CRH system and dopaminergic pathology. Stress exacerbates parkinsonian symptoms in animal models, and clinical observations suggest that psychological stress worsens motor function in PD patients. CRH may influence [alpha-synuclein](/mechanisms/alpha-synuclein) aggregation and propagation. Conversely, dopaminergic degeneration alters CRH system function; PD patients often show HPA axis dysregulation with elevated cortisol and altered CRH rhythms. CRH receptor antagonists may protect against stress-exacerbated dopaminergic neurodegeneration.
Huntington's Disease
Huntington's disease involves early CRH system dysfunction. Transgenic HD mice show altered CRH expression and HPA axis abnormalities. Mutant [huntingtin](/proteins/huntingtin-protein) (mHTT) affects CRH neuron function directly, potentially contributing to the anxiety, irritability, and depression that precede motor symptoms. CRH receptor antagonists have shown benefits in HD mouse models, reducing behavioral abnormalities and providing neuroprotection. The CRH system represents a potential therapeutic target for managing non-motor symptoms in HD.
Stroke and Traumatic Brain Injury
Following stroke or TBI, CRH levels increase dramatically as part of the acute stress response. While transient CRH elevation may be adaptive, excessive or prolonged CRH signaling contributes to secondary neuronal injury. CRH can exacerbate excitotoxicity, promote neuroinflammation, and impair recovery. CRHR1 antagonists are being investigated as neuroprotective agents in acute brain injury settings.
Therapeutic Implications
CRH Receptor Antagonists
- Antalarmin (CRHR1 Antagonist): Shown to reduce anxiety, improve stress resilience, and protect against stress-induced neurodegeneration in preclinical models. Limited brain penetration has hindered clinical development.
- Pexacerfont: A CRHR1 antagonist that reached clinical trials for anxiety and depression but was discontinued.
- NBI-35965, NBI-77858: Second-generation CRHR1 antagonists with improved pharmacological profiles.
Peptide-Based Approaches
- CRH Fragments: Truncated CRH peptides with antagonist properties are being explored.
- Urocortin Analogs: Selective CRHR2 agonists may have anxiolytic and cardioprotective effects without HPA axis activation.
Stress Reduction Strategies
- Cognitive Behavioral Therapy: Reduces CRH hyperactivity through top-down regulation.
- Mindfulness and Meditation: Lower basal CRH levels and improve stress resilience.
- Exercise: Normalizes HPA axis function and reduces CRH system hyperactivity.
Animal Models
- CRH Transgenic Mice: Overexpression of CRH leads to Cushing's syndrome-like phenotype with anxiety, depression, and accelerated aging.
- CRH Knockout Mice: Lack of CRH impairs stress responses, causing Addison's disease-like adrenal atrophy.
- CRHR1 Knockout Mice: Show reduced anxiety, impaired stress adaptation, and altered drug responses.
- CRHR2 Knockout Mice: Display increased anxiety, elevated HPA axis activity, and metabolic abnormalities.
Research Directions
Current research focuses on: (1) developing brain-penetrant CRH receptor antagonists for stress-related disorders; (2) understanding CRH interactions with amyloid and [tau](/proteins/tau) pathology; (3) exploring CRH as a biomarker for stress burden in neurodegeneration; (4) investigating CRH-targeted therapies for PD and HD; (5) developing non-pharmacological approaches to normalize CRH system function.
See Also
- [Proteins Index](/proteins)
- [Genes Index](/genes)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [Hypothalamus](/brain-regions/hypothalamus)
- [Amygdala](/brain-regions/amygdala)
- [Hippocampus](/brain-regions/hippocampus)
- [Neuropeptide Y](/proteins/neuropeptide-y-protein)
- [Somatostatin](/proteins/somatostatin-protein)
- [Galanin](/proteins/galanin-protein)
- [AVP](/proteins/vasopressin-protein)
External Links
- [UniProt: Corticotropin-Releasing Factor (CRH)](https://www.uniprot.org/uniprot/P06850)
- [IUPHAR/BPS Guide to Pharmacology: CRH Receptors](https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=31)
Background
The study of Corticotropin Releasing Hormone (Crh) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Vale W, Spiess J, Rivier C, Rivier J, Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin (1981)](https://doi.org/10.1126/science.6267699)
[Hauger RL, Risbrough V, Brauns O, Dautzenberg FM, Corticotropin releasing factor (CRF) and CRF-related peptides in psychiatric disorders (2022)](https://doi.org/10.1007/s40263-022-00941-1)
[Joels M, Baram TZ, The neuro-symphony of stress (2019)](https://doi.org/10.1038/nrn2632)
[Bale TL, Contarino A, Smith GW, et al, Corticotropin-releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and altered neuroendocrine responses to stress (2020)](https://doi.org/10.1038/35036539)
[De Kloet ER, Joels M, Holsboer F, Stress and the brain: From adaptation to disease (2018)](https://doi.org/10.1038/nrn1683)